Screener / SEC EDGAR /CIK 0001109354 /10-K filed Feb 27, 2026, compared with Mar 3, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Technology · Lab Instruments

Bruker Corp BRKR

Compare with peers Embed
New in the 10-K 23 paragraphs with nothing like them in the 10-K filed Mar 3, 2025 New in the 10-Q 32 paragraphs not in the 10-Q filed Aug 5, 2026 10-Q against the 10-K 0 risk factor paragraphs and sentences added or reworded

New risk paragraphs, branching off last year

Each branch is a paragraph in Risk Factors with nothing like it in the 10-K filed Mar 3, 2025. A box jumps to the paragraph as filed, below.

23 new

Paragraphs with nothing like them in last year's 10-K

Quoted exactly

23 paragraphs in Risk Factors of the 10-K filed Feb 27, 2026 with nothing like them in the 10-K filed Mar 3, 2025. Quoted exactly. Paragraphs that were only edited are under 10-K change.

•New U.S. and reciprocal tariffs that have been imposed, and remain subject to potential change and other uncertainties, including as a result of the recent U.S. Supreme Court decision, have had a material adverse effect on our business, results of operations and financial condition, and may continue to do so in the foreseeable future;

Read in the 10-K

•Delays in the release of Chinese government stimulus spending have had a material adverse effect on our business, results of operations and financial condition, and may continue to do so for the foreseeable future;

Read in the 10-K

•Our common stock ranks junior to our Series A Mandatory Convertible Preferred Stock with respect to dividends and amounts payable in the event of our liquidation, winding-up or dissolution;

Read in the 10-K

New U.S. and reciprocal tariffs that have been imposed, and remain subject to potential change and other uncertainties, have had a material adverse effect on our business, results of operations and financial condition, and may continue to do so in the foreseeable future.

Recently, the U.S. government has indicated its intent to modify U.S. trade policy and, in some cases, to renegotiate, or potentially terminate, certain existing bilateral or multi-lateral trade agreements. It has also imposed or increased tariffs on foreign imports into the United States from key trading partners, including Germany and Switzerland.

The tariff increases adopted in 2025, and the uncertainty associated with them in global markets, have resulted in lower than anticipated bookings and revenues and contributed to reduced gross margins, operating margins, and profitability, and may continue to

adversely affect our business, results of operations and financial condition for the foreseeable future. For example, during the year ended December 31, 2025, our results of operations were adversely impacted by an increase in cost of goods sold as a result of increased tariffs. Changes to tariffs and trade policies between the United States and foreign countries, such as what occurred during 2025, could reduce the purchasing power of our customers by increasing costs in their operations, which in turn may lead to decreased demand for our products or services. The magnitude and duration of any reduction in customer purchasing ability is difficult to reliably predict and quantify.

Moreover, tariffs and international trade arrangements may continue to change, potentially without warning, and to an extent that is difficult to predict. On February 20, 2026, the U.S. Supreme Court issued a ruling striking down certain tariffs previously imposed under the International Emergency Economic Powers Act (“IEEPA”). The ultimate availability, timing, and amount of any potential refunds of such tariffs remain highly uncertain and are subject to further legal, regulatory, and administrative developments. Following the Supreme Court’s decision, the U.S. presidential administration announced its intention to invoke other laws to collect tariffs and announced new tariffs on imports from all countries, in addition to any existing non-IEEPA tariffs.

There remains substantial uncertainty regarding the duration of existing and newly announced tariffs, potential changes or pauses to such tariffs, tariff levels, and whether further additional tariffs or other retaliatory actions may be imposed, modified, or suspended, and the impacts of such actions on our business. We are continuing to monitor and evaluate these “developments” and assess their potential impact on our business, financial condition, and results of operations.

Read in the 10-K

Delays in the release of Chinese government stimulus spending have had a material adverse effect on our business, results of operations and financial condition, and may continue to do so for the foreseeable future.

A significant portion of our revenue is derived from sales into China, some of which are directly funded through Chinese government stimulus programs for high-end medical and industrial research instrumentation. In 2025, the release of such Chinese government stimulus spending was delayed, which has negatively affected our sales growth into China and consequently has had an adverse effect on our business, results of operations, and financial condition in 2025. Our revenue in China for the year ended December 31, 2025, was $475.8 million and remained flat compared to $471.2 million for the year ended December 31, 2024. If the release of the Chinese government’s stimulus spending continues to be delayed or recurs, our sales into China may continue to be negatively affected and our business, results of operations, and financial condition may be adversely affected in the foreseeable future. Furthermore, we are subject to significant risks associated with the trading relationship between the U.S. and China, which is currently characterized by significant uncertainty. In addition to tariffs newly imposed by the U.S. and China, which have fluctuated and remain volatile, and may increase our costs, there may be additional import, export, tax, or other regulatory changes effected by the U.S. and Chinese governments in the future that could also adversely affect our business and results of operations.

Read in the 10-K
Show the other 9

•the impact of the recent U.S. government shutdown and its potentially adverse impact on the global economy;

Read in the 10-K

In addition to the foreign currency exposure associated with differences between where our products are manufactured and sold by us and our competitors, our exposure to currency exchange rate fluctuations results from the currency translation exposure

Read in the 10-K

As of December 31, 2025, we had an outstanding aggregate principal amount of debt totaling approximately $1.9 billion and had $900.0 million available for borrowing under the 2024 Revolving Credit Agreement, subject to compliance with financial covenant ratios.

Read in the 10-K

As of December 31, 2025, we were in compliance with all covenants under our debt agreements. Our failure to comply with any of these restrictions or covenants may result in an event of default under the applicable debt agreement, which would require waivers from participating banks and noteholders or permit acceleration of the debt under such debt agreement or a cross-default under all of our other debt agreements, and require us to prepay all of our outstanding debt before the applicable scheduled due dates, which would materially and adversely affect our financial condition.

Read in the 10-K

On July 4, 2025, the One Big Beautiful Bill Act (“OBBBA”) was enacted in the U.S. The OBBBA includes significant changes to U.S. corporate tax provisions of the Tax Cuts and Jobs Act. Notably, it allows an immediate deduction for domestic research and development expenditures, reinstates 100% bonus depreciation, and modifies the international tax framework. The legislation has multiple effective dates, with certain provisions effective starting in 2025 and others in the subsequent years. We have evaluated and reflected the OBBBA’s impact on its financial statements for the year ended December 31, 2025, which was not material. We will continue to monitor developments related to OBBBA and will update our disclosures as appropriate.

Read in the 10-K

The market price of our common stock could be influenced by outstanding Series A Mandatory Convertible Preferred Stock and could become more volatile and impacted by investors’ anticipation of the potential resale in the market of a substantial number of additional shares of common stock received upon conversion of the Series A Mandatory Convertible Preferred Stock.

Our common stock ranks junior to our Series A Mandatory Convertible Preferred Stock with respect to dividends and amounts payable in the event of our liquidation, winding-up or dissolution.

Our common stock ranks junior to our Series A Mandatory Convertible Preferred Stock with respect to the payment of dividends and amounts payable in the event of our liquidation, winding-up or dissolution. This means that, unless accumulated dividends have been paid or set aside for payment on all our outstanding Series A Mandatory Convertible Preferred Stock through the most recently completed dividend period, no dividends may be declared or paid on our common stock subject to limited exceptions. Likewise, in the event of our voluntary or involuntary liquidation, winding-up or dissolution, no distribution of our assets may be made to holders of our common stock until we have paid to holders of our Series A Mandatory Convertible Preferred Stock a liquidation preference equal to $250 per share plus accumulated and unpaid dividends.

Read in the 10-K

In addition, on September 8, 2025, we issued 2,760,000 shares of Series A Mandatory Convertible Preferred Stock with a dividend rate of 6.375% per annum on the liquidation preference thereof. The Series A Mandatory Convertible Preferred Stock ranks

senior to our common stock with respect to the payment of dividends. As long as any share of Series A Mandatory Convertible Preferred Stock is outstanding, unless all accumulated and unpaid dividends on the Series A Mandatory Convertible Preferred Stock for all preceding dividend periods have been declared and paid in full or declared and set apart for payment, we may not declare, pay or set apart for payment any dividends on our common stock. Dividends on the Series A Mandatory Convertible Preferred Stock are discretionary and cumulative. Holders of Series A Mandatory Convertible Preferred Stock will only receive dividends on their shares when, as, and if declared by our Board. These dividend obligations could impact our liquidity and reduce the amount of cash flows available for working capital, capital expenditures, growth opportunities, acquisitions, and other general corporate purposes. Our obligations to the holders of our Series A Mandatory Convertible Preferred Stock could also limit our ability to obtain additional financing, which could have an adverse effect on our financial condition. The preferential rights could also result in divergent interests between the holders of our Series A Mandatory Convertible Preferred Stock and holders of our Class A common stock. Additional risks related to the Series A Mandatory Convertible Preferred Stock are contained in the prospectus supplement filed with the SEC on September 8, 2025.

Read in the 10-K

action could have a material, adverse effect on our financial condition and results of operations. Further, the replacement of the European Union IVD Directive by the IVD Regulation (EU) 2017/746 in May 2022 has resulted in a stricter regime for manufacturers of IVDs. In accordance with the transitional provisions of the IVDR (Regulation (EU) 2017/746), our products currently comply with the applicable grace periods. Full conformity with all IVDR requirements must be achieved by December 31, 2029, for our in vitro diagnostic devices.

Read in the 10-K

We operate through a decentralized model where our business segments function as distinct entrepreneurial businesses with their own leadership teams responsible for day-to-day operations. This approach can lead to variations in how risks are managed, resources are allocated, and performance metrics are applied. If decentralized units fail to align with our company-wide risk management framework or if communication breakdowns occur, it could result in operational disruptions, increased costs, or failure to achieve expected synergies from acquisitions, materially impacting our business, financial condition, and results of operations.

Read in the 10-K

Paragraphs in the 10-Q filed Nov 5, 2026 that were not in the one before

New in the latest 10-Q

32 paragraphs in the 10-Q filed Nov 5, 2026 with nothing like them in the 10-Q filed Aug 5, 2026 (at least half the words must differ; new numbers alone do not count). Quoted exactly, grouped by the item heading above them. This is text that changed, not a judgement of how serious it is.

Financial statements and notes

Foreign currency translation (loss) gain before income taxes (15.9) 33.6 (67.3) 238.2

Read in the 10-Q

Income tax (benefit) expense on foreign currency translation adjustments (2.0) 13.9 (5.8) 15.4

Read in the 10-Q

Foreign currency translation (loss) gain after income taxes (13.9) 19.7 (61.5) 222.8

Read in the 10-Q

Gain (loss) on designated hedging instruments before income taxes 54.8 (2.8) 92.6 (249.2)

Read in the 10-Q

Income tax expense (benefit) related to designated hedging instruments 13.1 (0.7) 22.1 (59.6)

Read in the 10-Q
Show the other 27

Gain (loss) on designated hedging instruments after income taxes 41.7 (2.1) 70.5 (189.6)

Read in the 10-Q

The Mimetas division, a new division formed during the third quarter of 2026 following the acquisition of a majority interest in Mimetas B.V., as described in Note 3, Acquisitions.

Read in the 10-Q

BSI BMID develops, manufactures, and distributes innovative solutions for microbial identification, molecular diagnostics, and biomedical laboratory applications. The segment’s portfolio includes systems, software, consumables, reagents, and biological products used for microbial identification, infectious disease diagnostics, antimicrobial susceptibility and resistance testing, microbial genomics, laboratory workflow optimization, and specialty diagnostic applications. Revenues are generated from clinical laboratories, public health agencies, industrial, pharmaceutical, veterinary, food safety, and research markets worldwide.

Read in the 10-Q

BSI NANO, for which no changes were made to the reportable segment structure in connection with the reorganization.

Read in the 10-Q

BEST, for which no changes were made to the reportable segment structure in connection with the reorganization.

Read in the 10-Q

At September 30, 2026, the Company’s significant accounting policies, which are detailed in the 2025 Form 10-K, have not changed.

Read in the 10-Q

In connection with the Mimetas acquisition, the Company entered into an agreement with the noncontrolling interest holders that provides the Company with the right to purchase, and the noncontrolling interest holders with the right to sell, the remaining 6.0% at a contractually defined redemption value exercisable during the second quarter of 2029. The rights associated with the noncontrolling interests are contingently redeemable at the option of the Company or the noncontrolling interest holder during the option period, and therefore, is included in the mezzanine section of the consolidated balance sheet. Following the expiration of the option period, the Company may be required to purchase the noncontrolling interest at its fair market value upon the occurrence of certain contractually defined events.

Read in the 10-Q

The Company recorded the provisional determination of the fair value of the identifiable assets acquired and liabilities assumed based on the information available at the time of the issuance of these financial statements for the Mimetas acquisition. Accordingly, the values recognized are subject to change until the Company finalizes the allocation of consideration transferred during the measurement period, which is no later than one year from the acquisition date. The final determination may result in asset and liability values that are different than the preliminary estimates. The Company has finalized its valuation of the assets acquired and liabilities assumed related to all other acquisitions completed prior to the third quarter of 2026, within the measurement period, and no further material adjustments were recorded.

Read in the 10-Q

The results from the acquisitions included in the unaudited condensed consolidated financial statements of the Company from the acquisition dates through September 30, 2026, include revenues of $32.8 million and pre-tax losses totaling $2.6 million. The tax effect of pre-tax losses incurred will be included in the related jurisdictional tax returns of the subsidiaries.

Read in the 10-Q

The fair value measurement of the put option liability as of September 30, 2026 and December 31, 2025 included significant unobservable inputs as follows:

Read in the 10-Q

In connection with the acquisition of Mimetas, as further described in Note 3, Acquisitions, the Company established a new reporting unit, Mimetas, within the BSI BIOS segment during the third quarter of 2026, and assigned goodwill of $42.5 million to the reporting unit. Based on the preliminary purchase price allocation, the estimated fair value of the Mimetas reporting unit approximated its carrying value as of the acquisition date. As of the filing date of this Quarterly Report on Form 10-Q, the Company is not aware of any events or trends that are reasonably likely to have a negative impact on the estimated fair value of the Mimetas reporting unit.

Read in the 10-Q

As discussed in Note 1, Description of Business, effective July 1, 2026, the Company completed a reorganization of its reportable segments. Prior period segment information has been recast to conform to the new reportable segments.

Read in the 10-Q

September 30, 2026 September 30, 2025 BSI BIOS BSI BMID BSI NANO BEST Total BSI BIOS BSI BMID BSI NANO BEST Total ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── Revenue from external customers $ 1,154.8 $395.8 $770.4 $214.9 $ 2,535.9 $ 1,117.1 $373.3 $775.2 $193.7 $ 2,459.3 Intersegment revenue - - - 8.2 8.2 - - - 5.7 5.7 Total segment revenue $ 1,154.8 $395.8 $770.4 $223.1 $ 2,544.1 $ 1,117.1 $373.3 $775.2 $199.4 $ 2,465.0 Segment expenses: Cost of revenue $ 553.3 $144.9 $372.8 $175.6 $ 1,246.6 $ 565.0 $138.0 $373.3 $159.2 $ 1,235.5 Selling, general and administrative 266.0 88.4 202.3 17.6 574.3 261.3 85.5 212.2 16.6 575.6 Research and development 131.9 33.3 119.4 2.7 287.3 131.1 25.1 133.7 2.4 292.3 Segment operating income $ 203.6 $129.2 $75.9 $27.2 $ 435.9 $ 159.7 $124.7 $56.0 $21.2 $ 361.6 Reconciliation of total operating income: Corporate, elimination, and other (a) $ 90.6 $ 82.1 Adjustments and reconciling items (b) 491.4 287.6 Total consolidated operating loss $ (146.1) $ (8.1) Interest and other income (expense), net 7.0 (38.1) Loss before income taxes, equity in (losses) income of unconsolidated investees, net of tax, and noncontrolling interests in consolidated subsidiaries $ (139.1) $ (46.2) (a) Represents corporate costs and intersegment eliminations not allocated to the reportable segments. Unallocated costs include general and administrative expenses not directly incurred by the segments such as professional fees incurred for the quarterly reviews and annual audit of the consolidated financial statements, personnel costs of corporate accounting, finance, legal, and IT resources, and other expense items. (b) Adjustments and reconciling items consist of costs related to restructuring actions; acquisition and related integration expenses; amortization of acquired intangible assets; costs associated with the Company ’ s global IT transition initiatives; goodwill, intangible assets, other long-lived asset impairment charges; and other costs.

Read in the 10-Q

Net loss per common share attributable to Bruker Corporation common shareholders:

Read in the 10-Q

Interest Rate Lenders Credit Available ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── 2024 Revolving Credit Agreement (a) 1.12% $900.0 $115.0 $1.1 $783.9 Bank guarantees and working capital line Various 200.9 - 200.9 - Total revolving lines of credit $1,100.9 $115.0 $202.0 $783.9 (a) Any debt outstanding under the 2024 Revolving Credit Agreement is due at the end of its term in January 2029, and borrowings under this agreement may also be prepaid, at the Company’s option, in whole or in part without premium or penalty. On September 15, 2026, the Company entered into amendments to each of its four outstanding note purchase agreements, dated December 11, 2019, December 7, 2021, February 1, 2024, and February 8, 2024 (collectively, the “Amendments”). The Amendments modify certain covenant provisions permitting the Company, during two separate four-quarter availability periods (the first commencing with the fiscal quarter ending September 30, 2026), to convert such indebtedness into U.S. Dollars for purposes of the leverage ratio covenant using the more favorable of the applicable quarter-end exchange rate or the trailing twelve-month average exchange rate, subject to a maximum aggregate reduction of $150 million in the Consolidated Total Indebtedness component of the leverage ratio in any quarter. The Amendments also increased the limits on qualifying cash that offsets the overall debt balance used in the leverage ratio calculation, subject to specified limitations. The amendments to the February 1, 2024 and February 8, 2024 note purchase agreements also removed certain conditions on the Company’s ability to elect the increased leverage ratio permitted following a material acquisition. All other significant terms remain consistent with those described in Note 20, Debt, to the consolidated financial statements included in the 2025 Form 10-K.

Read in the 10-Q

The Mimetas division, a new division formed during the third quarter of 2026 following the acquisition of a majority interest in Mimetas B.V., as described in Note 3, Acquisitions.

Read in the 10-Q

• BSI NANO, for which no changes were made to the reportable segment structure in connection with the reorganization.

Read in the 10-Q

• BEST, for which no changes were made to the reportable segment structure in connection with the reorganization.

Read in the 10-Q

Prior period segment information has been recast to conform to the new reportable segments.

Read in the 10-Q

The non-GAAP organic revenue remained relatively flat during the three and nine months ended September 30, 2026.

Read in the 10-Q

September 30, September 30, 2026 2025 Dollar Percentage 2026 2025 Dollar Percentage

Read in the 10-Q

September 30, September 30, 2026 2025 Dollar Percentage 2026 2025 Dollar Percentage

Read in the 10-Q

market and the academic and government research market. Foreign currency fluctuations, primarily related to a stronger U.S. Dollar, reduced BSI BIOS revenue by approximately $4.0 million, or 0.9%. The increase in BEST revenue was driven primarily by higher demand from the hospital and clinical market. Geographically, revenue growth in Europe and North America was partially offset by lower revenue in China.

Read in the 10-Q

Gross profit increased by $49.9 million and gross profit margin improved by 500 basis points during the three months ended September 30, 2026, compared to the same period in 2025, driven primarily by a $19.6 million decrease in restructuring costs, cost savings initiatives that reduced product costs, and favorable revenue mix. The BSI BIOS segment contributed approximately $29.0 million of the increase in gross profit, driven primarily by lower product costs resulting from cost savings initiatives, with additional benefit from a $12.4 million decrease in restructuring costs, and the absence of intangible asset impairment charges of $4.3 million recorded in the prior-year period. The BSI BNANO segment contributed approximately $10.5 million of the increase, driven primarily by the absence of intangible asset impairment charges of $8.3 million and the absence of restructuring charges of $4.5 million recorded in the prior-year period, as well as lower product costs resulting from cost savings initiatives. These factors also contributed to improved gross profit margins in both segments.

Read in the 10-Q

Gross profit increased by $96.6 million and gross profit margin improved by 240 basis points during the nine months ended September 30, 2026, compared to the same period in 2025, driven primarily by a $16.8 million decrease in restructuring costs, cost savings initiatives that reduced product costs, a favorable net impact from U.S. tariffs, and higher revenue volume, partially offset by unfavorable revenue mix, higher purchased intangible asset amortization, and foreign exchange headwinds. The BSI BIOS segment contributed approximately $65.9 million of the increase in gross profit, driven primarily by higher revenue volume, lower product costs resulting from cost savings initiatives, a $11.5 million decrease in restructuring costs, a favorable net impact from U.S. tariffs, and the absence of intangible asset impairment charges of $9.9 million recorded in the prior-year period. The BSI BMID segment contributed approximately $18.1 million of the increase, driven primarily by higher revenue volume, a $4.2 million decrease in restructuring costs, a favorable net impact from U.S. tariffs, and lower product costs resulting from cost savings initiatives. These factors also contributed to improved gross profit margins in both segments.

Read in the 10-Q

In connection with the acquisition of Mimetas, as further described in Note 3, Acquisitions, to our unaudited condensed consolidated financial statements in this Quarterly Report on Form 10-Q, we established a new reporting unit, Mimetas, within the BSI BIOS segment during the third quarter of 2026 and assigned it $42.5 million of goodwill. Based on the preliminary purchase price allocation, the estimated fair value of the Mimetas reporting unit approximated its carrying value as of the acquisition date. As of the filing date of this Quarterly Report on Form 10-Q, we are not aware of any events or trends reasonably likely to negatively affect its estimated fair value.

Read in the 10-Q

notice. We continue to monitor these developments and assess their potential impact on our business, results of operations and financial condition.

Read in the 10-Q

The 10-Q's risk factors against the 10-K

Item 1A of the 10-Q filed Nov 5, 2026 against Item 1A of the 10-K filed Feb 27, 2026. A 10-Q repeats only the risks that changed, so a 10-K paragraph that is missing from it is not counted as removed. Added is a paragraph with nothing like it in the 10-K, Reworded a sentence that is in both with several words changed, Quiet changes a sentence in both where one to four words changed and one is a hedge or a modal (cut words struck through, new words highlighted). Text on the page, not a score; each links to the filing at sec.gov.

What the 10-Q itself says about its risk factors:In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in Part I, Item 1A. “Risk Factors” in our 2025 Form 10-K, which could materially affect our business, financial condition or future results. The risks described in this Quarterly Report on Form 10-Q and in our 2025 Form 10-K are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, and/or operating results.

Read in the 10-Q

1 paragraph in the 10-Q's Item 1A, and none of them adds, rewords or quietly edits a paragraph of the 10-K's.

Phrases used for the first time

Two-word phrases in Risk Factors of the 10-K filed Feb 27, 2026 that are in none of the 1 earlier 10-Ks stored, back to Mar 3, 2025

series mandatory ×18mandatory convertible ×18convertible preferred ×18chinese government ×4government stimulus ×4stimulus spending ×4current administration ×4stock ranks ×4liquidation winding-up ×4recent government ×3government shutdown ×3ranks junior ×3amounts payable ×3covenant ratios ×3remain subject ×2potential change ×2
Where each one is used
  • series mandatory: •Our common stock ranks junior to our Series A Mandatory Convertible Preferred Stock with respect to dividends and amounts payable in the event of our liquidation, winding-up or dissolution;
  • mandatory convertible: •Our common stock ranks junior to our Series A Mandatory Convertible Preferred Stock with respect to dividends and amounts payable in the event of our liquidation, winding-up or dissolution;
  • convertible preferred: •Our common stock ranks junior to our Series A Mandatory Convertible Preferred Stock with respect to dividends and amounts payable in the event of our liquidation, winding-up or dissolution;
  • chinese government: •Delays in the release of Chinese government stimulus spending have had a material adverse effect on our business, results of operations and financial condition, and may continue to do so for the foreseeable future;
  • government stimulus: •Delays in the release of Chinese government stimulus spending have had a material adverse effect on our business, results of operations and financial condition, and may continue to do so for the foreseeable future;
  • stimulus spending: •Delays in the release of Chinese government stimulus spending have had a material adverse effect on our business, results of operations and financial condition, and may continue to do so for the foreseeable future;
  • current administration: •We derive a significant portion of our revenue from international sales and are subject to the operational risks of doing business in foreign countries due to potential macroeconomic effects, including financial market volatility and disruption, inflationary concerns, changes in tax laws and regulations,...
  • stock ranks: •Our common stock ranks junior to our Series A Mandatory Convertible Preferred Stock with respect to dividends and amounts payable in the event of our liquidation, winding-up or dissolution;

The 10-K at sec.gov

Used at least twice, small words left out. Counted, not picked: a phrase can be new because the company renamed something.

What was taken out

7 paragraphs of last year's Risk Factors with nothing like them now. The longest are quoted.

Across all companies
The United States has implemented tariffs on certain imported goods and the new presidential administration in the US has imposed or threatened to impose additional tariffs on certain imported products, including reciprocal tariffs. These additional tariffs could include items imported by us from China or other countries. In addition, China has imposed tariffs on a wide range of American products in retaliation for these new American tariffs. As a result, there is a concern that the imposition of additional tariffs by the United States could result in the adoption of additional tariffs by...
In the 10-K filed Mar 3, 2025
The new U.S. presidential administration has imposed or threatened to impose tariffs ranging from 10-25% on a variety of countries, including China, Mexico, Canada and the EU, and products, including steel, aluminum, copper, automobiles, and digital services, and is likely to continue to do so in the future. In addition, the U.S. has threatened the imposition of reciprocal tariffs on those countries who impose unequal tariffs or taxes on U.S. exports. While to date, the only tariff increase in effect is the additional 10% tariff on U.S. imports from China, which is potentially increasing...
In the 10-K filed Mar 3, 2025
Our businesses and results of operations are affected by international, national and regional economic and political conditions. Our businesses or financial results may be adversely impacted by unfavorable changes in economic or political conditions in the countries and markets in which we operate, including, among others, adverse changes in interest rates or tax rates, volatility in financial and commodity markets, contraction in the availability of credit in the marketplace, higher tariffs, including those that have been or may be imposed by the new presidential administration in the...
In the 10-K filed Mar 3, 2025
Decentralization necessarily places significant control and decision-making powers in the hands of local management, which presents certain risks, including the risk that we may be slower to detect or react to compliance-related matters and that “company-wide” business initiatives may be more challenging or costly to implement, and the risk of noncompliance or failures higher than they may be in a more centralized operating environment. In addition, key business group resources and our corporate functions responsible for supporting our decentralized operations, may also not be able to...
In the 10-K filed Mar 3, 2025

Sources

Item 1A of each 10-K and 10-Q on EDGAR, quoted exactly. Each paragraph links to the filing at sec.gov.

Also

10-K change: what was reworded or cut, section by section.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/BRKR/export.csv") into a cell.

Next:10-K change
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.